Market Synopsis:
The bleeding disorder treatment industry is largely bolstered by the expanding patient pool, mounting awareness about the available treatment options, and the supportive compensation policies. Expiry of patents belonging to major brands can also present opportunities to generic drug manufacturers to make their foray into the bleeding disorder therapeutics market. the demand for bleeding disorder treatment options is quite robust in western economies in Europe and North America, in view of the exorbitant rates of the branded drugs. The demand for low-priced drugs is growing in developing and underdeveloped countries, given the reduced purchasing capacity of the patients in terms of medical treatment.
The Bleeding Disorders Treatment Market Share is expected to register a growth of significant CAGR 10.90% during the forecast period.
The American Society of Hematology reveals that in the year 2016, close to 20,000 Americans had hemophilia, with the prevalence higher in males. Hemophilia is a type of bleeding disorder that is rare and has been escalating at an alarming rate worldwide. Meanwhile, the burden of von Willebrand disease has been growing rapidly as well, emerging as one of the most common bleeding disorders in the United States resulting from clotting proteins.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6592
Competitive Dashboard:
- Shire Plc
- Bayer Pharmaceuticals
- Novo Nordisk A/S
- Pfizer Inc.
- Biogen Inc.
- CSL Behring
- Grifols
- Octapharma
- Sun Pharmaceutical Industries Ltd.
- BDI Pharma
- Ferring Pharmaceuticals
- Others
Global Bleeding Disorders Treatment Market: Segmental Analysis:
Bleeding Disorders Treatment Market, by Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease (vWD)
- Others
Bleeding Disorders Treatment Market, by Drug Class
- Plasma-derived coagulation factor concentrates market
- Global recombinant coagulation factor concentrate market
- Global others bleeding disorders treatment market
Bleeding Disorders Treatment Market, by Treatment
- Medication
- Desmopressin (DDAVP)
- Hormone replacement therapy
- Contraceptives
- Anti-fibrinolytic/clot-stabilizing drugs
- Fibrin sealants
- Drugs applied to cuts
- Pipeline analysis (phase I, phase II and phase III clinical trials)
Bleeding Disorders Treatment Market, by End-Users
- Hospitals
- Clinics
- Research Institutes
- Others
Regional Insights:
Geographically, the global bleeding disorders treatment market span across regions namely, Europe, America, Asia-Pacific, and the Middle East and Africa.
Among all the regions, the North American region is predicted to occupy the largest market share. The growth is credited to the early adoption of advanced medical technologies, and constant development by the major companies operating into the drugs. As per the Hemophilia Federation of America, more than 20,000 people are affected by hemophilia.
The European region occupies the second largest market share in the global market owing to factors such as advancement of technology, augmenting expenses in research, the necessity for effective and innovative therapies, and the decline in human health. As per Statista, approximately 149,764 people were diagnosed with hemophilia A. More than 10,811 people were diagnosed with other platelet disorders in 2016.
The Asia-Pacific region is likely to experience significant growth in the coming years owing to access to optimal treatment facilities. Additional factors gearing up the market growth are augmenting demand for government initiatives, high adoption rate, advanced technology, and increasing expenditure on healthcare. For instance, as per the annual report survey of 2015 provided by the World Federation of Hemophilia, around 17,346 million people are suffering from hemophilia.
Meanwhile, the Middle East & Africa occupies the smallest share owing to an underdeveloped healthcare sector, poor medical facilities, and a dearth of technical knowledge.
Industry Updates:
February 07, 2019: Roche has recently announced that it has joined the World Federation of Hemophilia Humanitarian Aid Program. They have taken the initiative in order to change the lack of access to treatment and care for people suffering from inherited bleeding disorders in developing countries.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/bleeding-disorders-treatment-market-6592
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
